Nervous System News and Research

Latest Nervous System News and Research

Higher vitamin D levels and sun exposure linked to lower risk of multiple sclerosis

People who spend more time in the sun and those with higher vitamin D levels may be less likely to develop multiple sclerosis (MS), according to a study published in the February 8, 2011, print issue of Neurology®, the medical journal of the American Academy of Neurology. MS is a chronic disease of the brain and spinal cord, usually with recurrent flare-ups of symptoms. It is often preceded by a first episode (or event) of similar symptoms lasting days to weeks.

8 Feb 2011

Researchers identify CHK1 protein may serve as treatment target for neuroblastoma

After analyzing hundreds of proteins produced by the DNA of tumor cells, researchers have identified one protein that may be central to a new treatment for the often-fatal childhood cancer neuroblastoma. Oncologists hope to translate the finding into pediatric clinical trials of a drug that blocks the protein's activity.

7 Feb 2011

PharmaMar initiates PM060184 Phase I clinical trial in patients with solid tumors

PharmaMar SA has announced the commencement of a Phase I clinical trial with PM060184 for patients with solid tumors. PM060184 is a marine-derived, synthetically-produced compound which has shown strong in vitro and in vivo antitumor activity and a favorable safety profile in preclinical toxicology studies. PM060184 is PharmaMar's sixth compound in clinical development.

7 Feb 2011

Acupuncture and exercise help women with PCOS

Acupuncture and physical exercise improve hormone levels and menstrual bleeding pattern in women with polycystic ovary syndrome (PCOS), reveals research from the University of Gothenburg, Sweden.

7 Feb 2011

AstraZeneca, Targacept commence TC-5214 Phase 2b clinical trial for major depressive disorder

AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.

7 Feb 2011

Progenics, Salix enter exclusive worldwide license agreement for RELISTOR

Progenics Pharmaceuticals, Inc. and Salix Pharmaceuticals, Ltd. today announced that they have entered into an exclusive worldwide (except Japan) agreement by which Salix has licensed rights to RELISTOR® (methylnaltrexone bromide).

7 Feb 2011

Positive results from EpiCept NP-1 Phase IIb trial in patients with CPN

EpiCept Corporation today announced positive results from a Phase IIb trial evaluating the efficacy and safety of EpiCept NP-1 in chemotherapy-induced peripheral neuropathy. EpiCept NP-1 is a topical analgesic cream containing two FDA-approved drugs, amitriptyline and ketamine, in development for the relief of pain from various peripheral neuropathies.

7 Feb 2011

Researchers trace scent signals from nose to higher centers of mouse brain

Mice know fear. And they know to fear the scent of a predator. But how do their brains quickly figure out with a sniff that a cat is nearby?

5 Feb 2011

Amgen, Pfizer present Enbrel new trial results against psoriasis at 69th AAD meeting in New Orleans, LA

Amgen and Pfizer Inc. today announced results from a new trial that demonstrated Enbrel significantly improved scalp involvement in adult patients with moderate to severe plaque psoriasis, compared with placebo. The data will be presented today at the 69th Annual American Academy of Dermatology meeting in New Orleans, La.

5 Feb 2011

ECR launches sleep aid product, Zolpimist Oral Spray in the US

NovaDel Pharma Inc. today announced that Zolpimist Oral Spray has been launched in the United States by ECR Pharmaceuticals, a subsidiary of Hi-Tech Pharmacal Co., Inc.. ECR Pharmaceuticals announced the immediate availability of Zolpimist Oral Spray, a novel delivery system of the most widely prescribed sleep aid in the US, zolpidem tartrate.

4 Feb 2011

Benefits and underutilization of ITB therapy for multiple sclerosis

A new scientific article has been published demonstrating the profound impact of spasticity on patients with multiple sclerosis and the benefits and underutilization of intrathecal baclofen (ITB) therapy from Medtronic, Inc. as a treatment option for these patients.

4 Feb 2011

Stem cells delivered intranasally improve motor function in Parkinson's disease

Stem cells, delivered intranasally, were found to substantially improve motor function in Parkinson's disease in a study co-authored by William H. Frey II, Ph.D, Director of the Alzheimer's Research Center, part of HealthPartners Research Foundation. Frey collaborated with Lusine Danielyan, MD, of University Hospital of Tubingen in Germany.

4 Feb 2011

Ceregene initiates enrollment and dosing in CERE-120 Phase 2b trial for Parkinson's disease

Ceregene, a biopharmaceutical company, announced today that it is progressing with enrollment and dosing in its CERE-120 Phase 2b multi-center, sham-surgery, double-blinded controlled trial in Parkinson's disease.

3 Feb 2011

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Merck announced today that data from the pivotal Phase III study with GARDASIL in males were published in the February 3 issue of the New England Journal of Medicine.

3 Feb 2011

International scientist team identifies gene mutation strongly linked to schizophrenia

In a major advance for schizophrenia research, an international team of scientists, led by Jonathan Sebat, PhD, assistant professor of psychiatry and cellular and molecular medicine at the University of California, San Diego School of Medicine, has identified a gene mutation strongly linked to the brain disorder - and a signaling pathway that may be treatable with existing compounds.

3 Feb 2011

Older people with metabolic syndrome may face high risk of developing memory loss

Older people with larger waistlines, high blood pressure and other risk factors that make up metabolic syndrome may be at a higher risk for memory loss, according to a study published in the February 2, 2011, online issue of Neurology, the medical journal of the American Academy of Neurology.

3 Feb 2011

Targeted delivery combination crosses brain protecting barrier and homes in on tumors

A targeted delivery combination selectively crosses the tight barrier that protects the brain from the bloodstream to home in on and bind to brain tumors, a research team led by scientists from The University of Texas MD Anderson Cancer Center reported in the January issue of the Journal of Clinical Investigation.

2 Feb 2011

Aphios enters subcontract with SAIC-Frederick to develop phospholipid nanoencapsulated camptothecin

Aphios® Corporation today announced that it has entered into a subcontract with SAIC-Frederick, a subsidiary of Science Applications International Corporation, to develop phospholipid nanoencapsulated camptothecin, Camposomes™, for the treatment of pancreatic and other cancers, supporting the NCI Alliance for Nanotechnology.

2 Feb 2011

Biogen Idec 2010 total revenues increase 8% to $4.7 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its full year and fourth quarter 2010 results.

1 Feb 2011

Specific brain network acts as event monitoring system

Wouldn't life be easy if everything happened as we anticipated? In reality, our brains are able to adapt to the unexpected using an inbuilt network that makes predictions about the world and monitors how those predictions turn out.

1 Feb 2011

Nervous System News and Research

Latest Nervous System News and Research

Higher vitamin D levels and sun exposure linked to lower risk of multiple sclerosis

Researchers identify CHK1 protein may serve as treatment target for neuroblastoma

PharmaMar initiates PM060184 Phase I clinical trial in patients with solid tumors

Acupuncture and exercise help women with PCOS

AstraZeneca, Targacept commence TC-5214 Phase 2b clinical trial for major depressive disorder

Progenics, Salix enter exclusive worldwide license agreement for RELISTOR

Positive results from EpiCept NP-1 Phase IIb trial in patients with CPN

Researchers trace scent signals from nose to higher centers of mouse brain

Amgen, Pfizer present Enbrel new trial results against psoriasis at 69th AAD meeting in New Orleans, LA

ECR launches sleep aid product, Zolpimist Oral Spray in the US

Benefits and underutilization of ITB therapy for multiple sclerosis

Stem cells delivered intranasally improve motor function in Parkinson's disease

Ceregene initiates enrollment and dosing in CERE-120 Phase 2b trial for Parkinson's disease

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

International scientist team identifies gene mutation strongly linked to schizophrenia

Older people with metabolic syndrome may face high risk of developing memory loss

Targeted delivery combination crosses brain protecting barrier and homes in on tumors

Aphios enters subcontract with SAIC-Frederick to develop phospholipid nanoencapsulated camptothecin

Biogen Idec 2010 total revenues increase 8% to $4.7 billion

Specific brain network acts as event monitoring system

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Nervous System News and Research

Latest Nervous System News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in